124 related articles for article (PubMed ID: 35314158)
1. Slow sulfide donor GYY4137 potentiates effect of paclitaxel on colorectal carcinoma cells.
Kajsik M; Chovancova B; Liskova V; Babula P; Krizanova O
Eur J Pharmacol; 2022 May; 922():174875. PubMed ID: 35314158
[TBL] [Abstract][Full Text] [Related]
2. Sodium/calcium exchanger is involved in apoptosis induced by H
Szadvari I; Hudecova S; Chovancova B; Matuskova M; Cholujova D; Lencesova L; Valerian D; Ondrias K; Babula P; Krizanova O
Nitric Oxide; 2019 Jun; 87():1-9. PubMed ID: 30849492
[TBL] [Abstract][Full Text] [Related]
3. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo.
Lee ZW; Zhou J; Chen CS; Zhao Y; Tan CH; Li L; Moore PK; Deng LW
PLoS One; 2011; 6(6):e21077. PubMed ID: 21701688
[TBL] [Abstract][Full Text] [Related]
4. H
Qabazard B; Masocha W; Khajah M; Phillips OA
Biomed Pharmacother; 2020 Jul; 127():110210. PubMed ID: 32407991
[TBL] [Abstract][Full Text] [Related]
5. Effects of fast versus slow-releasing hydrogen sulfide donors in hypertension in pregnancy and fetoplacental growth restriction.
Zochio GP; Possomato-Vieira JS; Chimini JS; da Silva MLS; Dias-Junior CA
Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1561-1568. PubMed ID: 31363805
[TBL] [Abstract][Full Text] [Related]
6. Effects of intranasal treatment with slow (GYY4137) and rapid (NaHS) donors of hydrogen sulfide in lipopolysaccharide-induced airway inflammation in mice.
Kaya-Yasar Y; Karaman Y; Bozkurt TE; Onder SC; Sahin-Erdemli I
Pulm Pharmacol Ther; 2017 Aug; 45():170-180. PubMed ID: 28645584
[TBL] [Abstract][Full Text] [Related]
7. Parenteral Na
Drapala A; Koszelewski D; Tomasova L; Ostaszewski R; Grman M; Ondrias K; Ufnal M
Acta Biochim Pol; 2017; 64(3):561-566. PubMed ID: 28753683
[TBL] [Abstract][Full Text] [Related]
8. H
Yurinskaya MM; Krasnov GS; Kulikova DA; Zatsepina OG; Vinokurov MG; Chuvakova LN; Rezvykh AP; Funikov SY; Morozov AV; Evgen'ev MB
Inflamm Res; 2020 May; 69(5):481-495. PubMed ID: 32157318
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological actions of the slow release hydrogen sulfide donor GYY4137 on phenylephrine-induced tone in isolated bovine ciliary artery.
Chitnis MK; Njie-Mbye YF; Opere CA; Wood ME; Whiteman M; Ohia SE
Exp Eye Res; 2013 Nov; 116():350-4. PubMed ID: 24145109
[TBL] [Abstract][Full Text] [Related]
10. GYY4137, an Extended-Release Hydrogen Sulfide Donor, Reduces NMDA-Induced Neuronal Injury in the Murine Retina.
Sone K; Mori A; Sakamoto K; Nakahara T
Biol Pharm Bull; 2018; 41(4):657-660. PubMed ID: 29607941
[TBL] [Abstract][Full Text] [Related]
11. GYY4137, a hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway.
Lu S; Gao Y; Huang X; Wang X
Int J Oncol; 2014 Apr; 44(4):1259-67. PubMed ID: 24535538
[TBL] [Abstract][Full Text] [Related]
12. The complex effects of the slow-releasing hydrogen sulfide donor GYY4137 in a model of acute joint inflammation and in human cartilage cells.
Li L; Fox B; Keeble J; Salto-Tellez M; Winyard PG; Wood ME; Moore PK; Whiteman M
J Cell Mol Med; 2013 Mar; 17(3):365-76. PubMed ID: 23356870
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological postconditioning against myocardial infarction with a slow-releasing hydrogen sulfide donor, GYY4137.
Karwi QG; Whiteman M; Wood ME; Torregrossa R; Baxter GF
Pharmacol Res; 2016 Sep; 111():442-451. PubMed ID: 27378570
[TBL] [Abstract][Full Text] [Related]
14. H
Untereiner AA; Oláh G; Módis K; Hellmich MR; Szabo C
Biochem Pharmacol; 2017 Jul; 136():86-98. PubMed ID: 28404377
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen sulfide donors prevent lipopolysaccharide-induced airway hyperreactivity in an in vitro model of chronic inflammation in mice.
Karaman Y; Kaya-Yasar Y; Bozkurt TE; Sahin-Erdemli I
Basic Clin Pharmacol Toxicol; 2021 May; 128(5):652-660. PubMed ID: 33369105
[TBL] [Abstract][Full Text] [Related]
16. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer.
Druzhyna N; Szczesny B; Olah G; Módis K; Asimakopoulou A; Pavlidou A; Szoleczky P; Gerö D; Yanagi K; Törö G; López-García I; Myrianthopoulos V; Mikros E; Zatarain JR; Chao C; Papapetropoulos A; Hellmich MR; Szabo C
Pharmacol Res; 2016 Nov; 113(Pt A):18-37. PubMed ID: 27521834
[TBL] [Abstract][Full Text] [Related]
17. Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance.
Lee ZW; Teo XY; Tay EY; Tan CH; Hagen T; Moore PK; Deng LW
Br J Pharmacol; 2014 Sep; 171(18):4322-36. PubMed ID: 24827113
[TBL] [Abstract][Full Text] [Related]
18. Hydrogen Sulfide Donor GYY4137 Acts Through Endothelial Nitric Oxide to Protect Intestine in Murine Models of Necrotizing Enterocolitis and Intestinal Ischemia.
Drucker NA; Jensen AR; Te Winkel JP; Markel TA
J Surg Res; 2019 Feb; 234():294-302. PubMed ID: 30527488
[TBL] [Abstract][Full Text] [Related]
19. GYY4137, a novel hydrogen sulfide-releasing molecule, protects against endotoxic shock in the rat.
Li L; Salto-Tellez M; Tan CH; Whiteman M; Moore PK
Free Radic Biol Med; 2009 Jul; 47(1):103-13. PubMed ID: 19375498
[TBL] [Abstract][Full Text] [Related]
20. Sulphide signalling potentiates apoptosis through the up-regulation of IP3 receptor types 1 and 2.
Lencesova L; Hudecova S; Csaderova L; Markova J; Soltysova A; Pastorek M; Sedlak J; Wood ME; Whiteman M; Ondrias K; Krizanova O
Acta Physiol (Oxf); 2013 Aug; 208(4):350-61. PubMed ID: 23582047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
